These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 7505980)
21. Radiation therapy for local recurrence of prostate cancer after radical prostatectomy. Takayama TK; Lange PH Urol Clin North Am; 1994 Nov; 21(4):687-700. PubMed ID: 7526515 [TBL] [Abstract][Full Text] [Related]
22. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy. Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734 [TBL] [Abstract][Full Text] [Related]
23. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735 [TBL] [Abstract][Full Text] [Related]
24. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574 [TBL] [Abstract][Full Text] [Related]
25. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors]. Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198 [TBL] [Abstract][Full Text] [Related]
26. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793 [TBL] [Abstract][Full Text] [Related]
27. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457 [TBL] [Abstract][Full Text] [Related]
28. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy. Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709 [TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Pound CR; Partin AW; Epstein JI; Walsh PC Urol Clin North Am; 1997 May; 24(2):395-406. PubMed ID: 9126237 [TBL] [Abstract][Full Text] [Related]
30. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence. Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456 [TBL] [Abstract][Full Text] [Related]
31. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752 [TBL] [Abstract][Full Text] [Related]
33. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. Witherspoon LR; Lapeyrolerie T J Urol; 1997 Apr; 157(4):1322-8. PubMed ID: 9120931 [TBL] [Abstract][Full Text] [Related]
34. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Blute ML; Bostwick DG; Bergstralh EJ; Slezak JM; Martin SK; Amling CL; Zincke H Urology; 1997 Nov; 50(5):733-9. PubMed ID: 9372884 [TBL] [Abstract][Full Text] [Related]
35. Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer. Naito S Jpn J Clin Oncol; 2005 Jul; 35(7):365-74. PubMed ID: 15976063 [TBL] [Abstract][Full Text] [Related]
36. Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy? Godoy G; Tareen BU; Lepor H Urology; 2009 Jul; 74(1):167-70. PubMed ID: 19406457 [TBL] [Abstract][Full Text] [Related]
37. Prediction of biochemical relapse for stage pT3 prostate cancer following radical prostatectomy. Wu TT; Wang JS; Lu CM; Lee YH; Huang JK Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):124-30. PubMed ID: 10677923 [TBL] [Abstract][Full Text] [Related]
38. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. San Francisco IF; Regan MM; Olumi AF; DeWolf WC J Urol; 2004 Apr; 171(4):1492-9. PubMed ID: 15017206 [TBL] [Abstract][Full Text] [Related]
39. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy. Haese A; Huland E; Graefen M; Hammerer P; Noldus J; Huland H J Urol; 1999 Apr; 161(4):1206-11. PubMed ID: 10081870 [TBL] [Abstract][Full Text] [Related]
40. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]